| Titre : | Daily Vibrotactile Stimulation Exhibits Equal or Greater Spasticity Relief Than Botulinum Toxin in Stroke (2023) |
| Auteurs : | Caitlyn Seim ; Bingxian Chen ; Chuzhang Han ; David Vacek ; Alexis Lowber ; Maarten Lansberg ; Allison M. Okamura |
| Type de document : | Article |
| Dans : | Archives of Physical Medicine and Rehabilitation (Vol. 104, n° 10, 2023) |
| Article en page(s) : | p. 1565-1572 |
| Note générale : | https://doi.org/10.1016/j.apmr.2023.03.031 |
| Langues: | Anglais |
| Descripteurs : |
HE Vinci Accident vasculaire cérébral (AVC) ; Dispositifs électroniques portables ; Réadaptation ; Spasticité musculaire ; Stimulation électrique ; Stimulation sensorielle ; Toxines botuliniques de type A ; Vibration |
| Résumé : | Objective To test the feasibility and efficacy of the VibroTactile Stimulation (VTS) Glove, a wearable device that provides VTS to the impaired limb to reduce spastic hypertonia. Design Prospective 2-arm intervention study?including 1 group of patients who use Botulinum toxin (BTX-A) for spasticity and 1 group of patients who do not use BTX-A. Setting Participants were recruited through rehabilitation and neurology clinics. Participants Patients with chronic stroke (N=20; mean age=54 years, mean time since stroke=6.9 years). Patients who were previously receiving the standard of care (BTX-A injection) were eligible to participate and started the intervention 12 weeks after their last injection. Intervention Participants were instructed to use the VTS Glove for 3 hours daily, at home or during everyday activities, for 8 weeks. Main Outcome Measures Spasticity was assessed with the Modified Ashworth Scale and the Modified Tardieu Scale at baseline and then at 2-week intervals for 12 weeks. Primary outcomes were the difference from baseline and at week 8 (end of VTS Glove use) and week 12 (4 weeks after stopping VTS Glove use). Patients who were receiving BTX-A were also assessed during the 12 weeks preceding the start of VTS Glove use to monitor the effect of BTX-A on spastic hypertonia. Range of motion and participant feedback were also studied. Results A clinically meaningful difference in spastic hypertonia was found during and after daily VTS Glove use. Modified Ashworth and Modified Tardieu scores were reduced by an average of 0.9 (P=.0014) and 0.7 (P=.0003), respectively, at week 8 of daily VTS Glove use, and by 1.1 (P=.00025) and 0.9 (P=.0001), respectively, 1 month after stopping VTS Glove use. For participants who used BTX-A, 6 out of 11 showed greater change in Modified Ashworth ratings during VTS Glove use (mean=-1.8 vs mean=-1.6 with BTX-A) and 8 out of 11 showed their lowest level of symptoms during VTS Glove use (vs BTX-A). Conclusions Daily stimulation from the VTS Glove provides relief of spasticity and hypertonia. For more than half of the participants who had regularly used BTX-A, the VTS Glove provided equal or greater symptom relief. |
| Disponible en ligne : | Oui |
| En ligne : | https://login.ezproxy.vinci.be/login?url=https://www.sciencedirect.com/science/article/pii/S0003999323002381 |
Bibliothèques HE Vinci
